Joel W Neal

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Current management of small cell lung cancer
    Joel W Neal
    Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Chest Med 32:853-63. 2011
  2. doi request reprint Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Treat Options Oncol 11:36-44. 2010
  3. pmc The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Future Oncol 6:1827-32. 2010
  4. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
  5. doi request reprint Aflibercept in lung cancer
    Joel W Neal
    Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
    Expert Opin Biol Ther 13:115-20. 2013

Detail Information

Publications5

  1. doi request reprint Current management of small cell lung cancer
    Joel W Neal
    Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Chest Med 32:853-63. 2011
    ..Numerous promising targeted therapies and other agents are still in development...
  2. doi request reprint Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Treat Options Oncol 11:36-44. 2010
    ..Inhibitors of the hedgehog (Hh) signaling pathways have some early clinical promise in both NSCLC and small cell lung cancer (SCLC), and larger studies using these agents are eagerly anticipated...
  3. pmc The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Future Oncol 6:1827-32. 2010
    ..A subset of patients whose tumors had EGF receptor mutations had a higher magnitude of benefit from maintenance treatment. Therefore, maintenance erlotinib should be considered in the treatment of patients with NSCLC...
  4. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
    ....
  5. doi request reprint Aflibercept in lung cancer
    Joel W Neal
    Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
    Expert Opin Biol Ther 13:115-20. 2013
    ..Aflibercept (VEGF Trap) is a recombinant VEGF receptor-antibody protein fusion with higher affinity for VEGF-A than bevacizumab, plus affinity for VEGF-B and placental growth factor (PlGF)...